Skip to main content
European Commission logo print header

Translational studies of HEAD and neck cancer in South America and Europe

Project description

Boosting predictors of prognosis of head and neck cancer

Head and neck cancer (HNC) is one of the most common types of cancer in Europe. More than 150 000 new patients are diagnosed each year. Even though it is the sixth most common cancer in Europe and South America, there is little awareness of this, with patient outcomes remaining poor for those diagnosed in the later stages. Accurate assessment of the prognosis of HNC cases also allows for appropriate treatment decisions. The EU-funded HEADSpAcE project will investigate the reasons for late diagnosis in Europe and South America. It will provide genomic evidence of strong predictors of prognosis that will have the potential to improve care and reduce treatment-related morbidity.

Objective

Worldwide, more than 550,000 new cases of head and neck cancer (HNC) occur each year, resulting in approximately 300,000 deaths annually. It is the 6th most common cancer in both Europe and South America. A major reason for the high mortality rate for this cancer is the late stage of diagnosis for many patients. Accurate assessment of the prognosis of HNC cases also allows for appropriate treatment decisions. HEADSpAcE will bring together a consortium of 18 partners with a long and successful record of collaboration in HNC. The impact of HEADSpAcE will be to understand reasons for late diagnosis and reduce the proportion of HNC that are diagnosed at a very late stage. It will identify the most appropriate fashion for diagnosis cancer caused by human papilloma virus, and also provide genomic evidence of strong predictors of prognosis that will have the potential to improve care and reduce treatment related morbidity. We will also develop guidelines for implementation into clinical care.

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2018-Single-Stage-RTD